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Kaposi’s sarcoma-associated herpesvirus T cell
responses in HIV seronegative individuals from
rural Uganda
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Marjorie Nakibuule1, Stephen Cose1,4, Rosemary Rochford2, Robert Newton 5 & Denise Whitby 3✉
T cell responses to Kaposi’s sarcoma-associated herpesvirus (KSHV) are likely essential in
the control of KSHV infection and protection from associated disease, but remain poorly
characterised. KSHV prevalence in rural Uganda is high at >90%. Here we investigate IFN- γ
T cell responses to the KSHV proteome in HIV-negative individuals from a rural Ugandan
population. We use an ex-vivo IFN- γ ELISpot assay with overlapping peptide pools spanning
83 KSHV open reading frames (ORF) on peripheral blood mononuclear cells (PBMC) from
116 individuals. KSHV-specific T cell IFN- γ responses are of low intensity and heterogeneous,
with no evidence of immune dominance; by contrast, IFN- γ responses to Epstein–Barr virus,
Cytomegalovirus and influenza peptides are frequent and intense. Individuals with KSHV
DNA in PBMC have higher IFN- γ responses to ORF73 (p= 0.02) and lower responses to
K8.1 (p= 0.004) when compared with those without KSHV DNA. In summary, we
demonstrate low intensity, heterogeneous T cell responses to KSHV in immune-competent
individuals.
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he adaptive response to Kaposi sarcoma-associated her-
pesvirus (KSHV) is important in protecting from KSHV-
associated malignancies, i.e., Kaposi’s sarcoma (KS), mul-
ticentric Castleman’s disease and primary effusion lymphoma1,2.
This is shown by the substantial increase in the risk of developing
KS- and other KSHV-associated malignancies in immunocom-
promised individuals3,4. A higher frequency of KSHV-specific
T cells has been reported in KS patients who achieve complete
remission compared to cases with unresolved KS5–7. In com-
parison to KS patients, more frequent and higher KSHV-specific
T cell responses have been reported in asymptomatic individuals8.
Treatment with highly active antiretroviral therapy of AIDS-KS
patients has been associated with an improved KSHV-specific T
cell response, correlating with KS regression9,10. Furthermore, the
pivotal role of T cells in controlling other herpesviruses, including
Epstein–Barr virus (EBV), CMV and HSV, has been well
investigated11,12, although similar evidence (specific requirements
and immunodominant epitopes) for KSHV is less well under-
stood. Understanding T cell responses to KSHV is important for
the development of KSHV vaccines and immunotherapy for KS.
During the adaptive immune response to viral infections,
CD8+ T cells play a vital role in killing virally-infected cells and
producing effector cytokines, while CD4+ T cells produce cyto-
kines to enhance CD8+ T cells cytotoxic killing of infected cells.
Several studies have reported a predominant role of cytotoxic
CD8+ T cells in the control of classic, iatrogenic and AIDS-
related KS1,2,13,14. However, these studies have focused on HLA-
A2 epitopes, a frequent haplotype in Caucasians15, and were
performed in mostly, non-KS endemic areas, with only two stu-
dies reporting cellular responses to KSHV in sub-Saharan Africa
and only then in a limited number of study participants16,17.
The ~165 kB double-stranded DNA KSHV genome encodes
about 90 proteins18 with a very high number of potential T cell
epitopes in each protein. Previous studies have identified epitopes
in individual participants, but these have not been confirmed in
other studies. We developed a systematic approach using over-
lapping peptides to the entire KSHV proteome to investigate
KSHV cellular immunity in US healthy donors and patients with
KSHV-related disease19,20. We made peptide pools corresponding
to each KSHV open reading frame (ORF) and measured
responses by IFN-γ ELISpot. We showed that participants
responded typically to between one and five peptide pools but,
that there was no overlap between participants in the peptide
pools recognised. Responses were heterogeneous and generally
low compared to responses to EBV and CMV and suggested a
lack of immunodominance.
Detection of KSHV DNA as well as its quantity in peripheral
blood mononuclear cells (PBMC) has been associated with KS
disease progression21–24 and increased HIV viremia in HIV-
infected individuals25. In individuals without KS- or any other
KSHV-associated disease, we have previously shown that KSHV
DNA in PBMC was associated with increased KSHV antibody
levels to lytic KSHV protein K8.1 and to malaria parasitaemia26.
An association between increased lytic KSHV antibody levels and
KS disease risk has also been reported27. Similarly in KS patients,
correlations between KSHV in PBMC with increasing KSHV lytic
antibody titres have been shown25. In combination, these data
suggest that KSHV in PBMC corresponds to viral reactivation
and disease progression. Therefore we hypothesise that loss of
KSHV T cell control leads to increased KSHV DNA in PBMC.
In the current study, we use our systematic approach to
investigate T cell responses to nearly the entire KSHV proteome
in 116 KSHV+HIV-negative individuals with a wide age range
from a rural cohort in Uganda, where both KSHV and KS are
endemic. In addition, we compare T cell responses among KSHV
seropositive individuals with and without KSHV DNA in PBMC.
Results
Study population. A total of 116 KSHV seropositive individuals
aged 6–87 years are included in the analysis. Of these, 13%
(15/116) are 6–17 years old, 74% (86/116) are 18–50 years old
and 13% (15/116) are 51–87 years of age. Overall, 51% (59/116)
are male and 41% (47/116) have detectable KSHV DNA in PBMC
(Table 1).
The pattern of IFN-γ responses to KSHV antigens compared to
controls (EBV and CEF). Most of these individuals respond to
EBV (76%) and CEF (69%) antigens (Table 1). Eighty-nine
individuals out of 116 have a positive IFN−γ response to at least
one KSHV ORF (77%); 44% respond to one to two KSHV ORFs
and 33% respond to three or more KSHV ORFs. One individual
responds to 37 KSHV ORFs (Table 1).
Next, we compare the magnitude of the IFN-γ responses. The
magnitude of IFN-γ responses to CEF (Figs. 1 and 2) and EBV
(Fig. 2) range from 40 spot forming cell (SFC)/million PBMC to
3713 and 3891–SFC/million PBMC, respectively (Supplementary
Fig. 1). There is no consistent pattern of response to KSHV ORFs
(Fig. 3), and when an IFN-γ response is observed to individual
KSHV ORFs, the magnitude of the response is generally low
(Figs. 1 and 2 and Supplementary Data 1 and 2). The raw data
used to draw Fig. 1 are shown in Supplementary Data 1, while the
Table 1 Proportions of individuals responding with IFN-γ production and their overall characteristics.
All individuals analysed (n= 116)
Age mean (range) 34 (6–87)
6–17 years 13% (15/116)
18–50 years 74% (86/116)
51–87 years 13% (15/116)
Sex, males 51% (59/116)
Proportion of individuals with KSHV DNA in PBMC 41% (47/116)
Proportion of individuals with a positive IFN-γ response to at least one KSHV ORF 77% (89/116)
Proportion of individuals with positive IFN-γ responses to one to two KSHV ORF 44% (51/116)
Proportion of individuals with positive IFN-γ responses to three or more (up to 37) KSHV ORF 33% (38/116)
Proportion of individuals with positive IFN-γ responses to CEFa 69% (80/116)
Proportion individuals with positive IFN-γ responses to EBV 76% (58/76)
KSHV DNA measured using real-time PCR, IFN-γ responses of PBMC were detected and quantified using an ex vivo ELISpot assay.
Source data are provided as a Source Data file.
PBMC peripheral blood mononuclear cell.
aCMV+ EBV+ flu (CEF) peptides cocktail.
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raw data used to draw Fig. 2 are shown in Supplementary Data 2.
Furthermore, there is no pattern observed either by age group or
sex. However, we observe that the proportion of individuals
responding to at least one KSHV ORF increased with age (Fig. 4a)
and is similar in males and females (Fig. 4b). Furthermore, the
number of reactive KSHV ORFs per individual increases with the
increasing age of the study participant (Supplementary Fig. 2).
Among KSHV peptide pools, K8.1 is the most commonly
recognised ORF (38%) followed by ORF73 (21%) (Fig. 3).
Surprisingly, 23% of individuals respond to a Simian immuno-
deficiency virus (SIV) peptide (Fig. 3).
IFN-γ responses K8.1 and ORF73 by KSHV DNA detection in
PBMC. Since K8.1 and ORF73 are the most frequently recog-
nised ORFs (45% of individuals react to either K8.1 or ORF73
and 11% react to both), we determine if IFN-γ responses to K8.1,
ORF73 and positive controls (EBV and CEF) are related to the
detection of KSHV DNA in PBMC. Individuals without KSHV
DNA in PBMC have higher IFN-γ responses to K8.1 compared
to those with KSHV DNA in PBMC (Fig. 5a, g). Furthermore,
there is a trend towards a negative correlation between IgG
antibody levels to K8.1 and IFN-γ responses to K8.1 (Supple-
mentary Fig. 3). As previously reported26, anti-K8.1 IgG anti-
body levels are higher in those with detectable KSHV DNA in
PBMC (Fig. 5b) while no difference is observed with anti-ORF73
antibody levels (Fig. 5c). Conversely, individuals without KSHV
DNA in PBMC have lower IFN-γ responses to ORF73 compared
to those without KSHV DNA in PBMC (Fig. 5d, h). There is no
difference in IFN-γ responses to both EBV (Fig. 5e) and CEF
(Fig. 5f) among individuals with and without KSHV DNA in
PBMC.
IFN-γ responses to individual peptides within the K8.1 peptide
pool. Results from four samples tested for K8.1 individual peptide
IFN-γ responses show diversity in the responses. The individuals’
GPC-69, GPC-313, GPC-371 and GPC-339 responded to 10, 7, 2
and 1 K8.1 peptides, respectively (Table 2). Three (GPC-69, GPC-
371 and GPC-339) out of four individuals responded to peptide
44 (peptide sequence: YLCVPRCRRKKPYIV).
Number of reactive antigens per individual in relation to
KSHV DNA in PBMC. As mentioned above, 23%, 44% and 33%
of individuals respond to no KSHV antigen, 1–2 antigens and
3–37 antigens, respectively. To explore whether there is a corre-
lation between detectable levels of KSHV in PBMC, which could
be indicative of a loss of T-cell control, we then compare the three
groups (no response, response to 1–2 antigens or 3–37 antigens)
focusing on those with KSHV DNA in PBMC. Individuals who
respond to 1–2 KSHV antigens have the lowest levels of KSHV
DNA in PBMC, while those without any IFN-γ response to
KSHV and those with IFN-γ responses to three or more KSHV
antigens have similar levels of KSHV DNA in PBMC (Fig. 6a).
When we broke the groups into five smaller groups, we observe a
decline in KSHV viral load from the non-responders to those
responding to two peptide pools, then an increase in KSHV viral
load thereafter (Fig. 6b). The low levels of KSHV viral load among
those responding to 1–2 peptide pools and the higher levels of
KSHV viral load among those responding to 3 or more peptide
pools could be explained by the fact that very few individuals
reacting to ORF73 were in the 1–2 peptide pool group.
Discussion
Previous studies showed that individuals without KS disease









































































































































































































































































































































































































Fig. 1 KSHV-specific IFN-γ responses of 40 Ugandans aged 6–87 years. Ex vivo ELISpot assay was used to determine IFN-γ responses to KSHV
overlapping peptide pools. Spot forming cells (SFC) per million PBMCs were recorded for each reaction. The intensity of the purple colour correlates with
the number of SFC per million PBMCs. The raw data used to draw this graph are shown in Supplementary Data 2. SIV Simian immunodeficiency virus, CEF
CMV+ EBV+ flu cocktail, EBV Epstein–Barr virus. Heatmap drawn in GraphPad Prism version 8.0.1. Source data are provided as a Source Data file.
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emphasising a key contribution of insufficient KSHV T cell
responses to the risk of KS disease. Contrary to this, we have
shown previously that US patients with KSHV-related disease
responded to a greater number of ORFs compared to asymp-
tomatic KSHV-infected healthy participants, but the magnitude
of the responses was similar20. Others have also shown that
individuals with HIV infection have low KSHV-specific T cell
responses compared to HIV-negative individuals, likely due to
the effect of HIV on CD4 T cells31,32. Furthermore, the
reduction in HIV viral load and increase in CD4 count corre-
lated with increased KSHV-specific T cell immunity7. In light of
these mixed findings, studies investigating KSHV T cell
responses in HIV-negative individuals were needed33. We,
therefore, in the current study focus on HIV-negative indivi-
duals without any apparent form of KSHV-associated disease
who are KSHV seropositive and from a KSHV/KS endemic
area, in order to understand KSHV T cell responses in the
absence of overt immune suppression. In this study, we show
that the intensity IFN-γ T cell responses to KSHV in a Ugandan
cohort are very low and infrequent compared to T cell
responses to other herpesviruses such as EBV and CMV as
well as to influenza virus. While low-intensity IFN-γ T cell
responses to KSHV antigens have been reported previously,
particularly in patients with KS2,17,34, our study (the largest in
terms of the number of participants) is the first to report this in
apparently healthy HIV-negative individuals in a KSHV ende-
mic region. It may have been expected that in this endemic
area, where KSHV reactivation is likely more frequent than in
low endemicity regions such as the US, T cell responses to















































































































































































































































































































































































































Fig. 2 KSHV-specific IFN-γ responses of 76 Ugandans aged 18–50 years. Ex vivo ELISpot assay was used to determine IFN-γ responses to KSHV
overlapping peptide pools. Spot forming cells (SFCs) per million PBMCs were recorded for each reaction. The intensity of the purple colour correlates with
the number of SFCs per million PBMCs. The raw data used to draw this graph are shown in Supplementary Data 1. SIV Simian immunodeficiency virus, EBV
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Fig. 3 Proportion of individuals with IFN-γ responses to various KSHV ORFs and controls peptide pools. Dots represent the percentage of individuals
reacting to the different KSHV antigens. Error bars represent 95% confidence intervals. N= 116 study participants. SIV Simian immunodeficiency virus, EBV
Epstein–Barr virus, CEF CMV+ EBV+ flu cocktail. Graph drawn in GraphPad Prism version 8.0.1. Source data are provided as a Source Data file.
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from the current study are similar to those seen in healthy US
participants20.
The low level of T cell responses to KSHV differs from the
robust T cell responses to other human herpesviruses and
requires further investigations. We think, however, that the level
of responses is not due to a technical artefact such as the con-
centration of peptides as we stringently evaluated this possibility
in our assay development and validation20. Although responses to
KSHV are low on average, some individuals had very high
responses to certain peptide pools. For example, we observed
3243 SFU per million cells as the maximum response for the K8.1
peptide pool that is very comparable to 3891–SFU per million
cells that is the maximum response to the EBV peptide pool. In
addition, responses to individual peptides shown in Table 2 are
comparable to responses to peptide pools. Furthermore, the
number of peptides per KSHV ORF is comparable to the number
of peptides in the EBV peptide pool. KSHV has been shown to
encode for numerous proteins including host protein homologues
that aid host immune evasion35,36. For instance, MHC class I,
MHC class II, CD1d, CD31, CD54, B7-2, MICA, MICB and IFN-
γR1 degradation by KSHV RTA, K5 and K3 proteins had been
shown to promote CD4+ T cells, CD8+ T cells and NK cells
dysfunction37. However, the individuals we studied do not have
any form of KSHV-associated disease and are of a wide age range,
including older individuals who had probably been infected with
KSHV for decades. Therefore, the responses in these individuals,
while of low intensity and heterogenous, were sufficient to control
KSHV in terms of disease risk. Myoung et al. showed suppression
of spontaneous KSHV reactivation in tonsillar B cells by activated
tonsillar CD4 T cells in an MHC-independent manner38. How-
ever, these results have not been replicated and the mechanism of
this unspecific KSHV control was not investigated. Future studies
investigating these findings further are warranted.
In addition to the T cell responses being low in intensity and
frequency, they were very diverse in targeting KSHV antigens
across sexes and age groups. Nevertheless, in combination, we
have shown that a large number of individuals responded to at
least one KSHV antigen (77%). Response to at least one KSHV
antigen increases with age and is similar in males and females.
This finding is consistent with the early age of infection with
KSHV in endemic areas. This implies that the longer someone is
infected with the virus, the higher the probability of developing
detectable T cells specific for at least one KSHV antigen.
Individuals who responded to one to two KSHV antigens have
a lower KSHV viral load compared to those without any detect-
able KSHV-specific T cell response. Surprisingly, also individuals
responding to three or more antigens have a higher KSHV viral
load similar to those without any KSHV T cell response. This may
imply that T cell response to an individual viral protein such as
K8.1 could suppress viral load.
Most studies have failed to show any association between
KSHV viral load in PBMC and T cell responses5,16,30. This might
have been attributed to the small sample sizes of these previous
studies. Nevertheless, one study showed increased T cell
responses to ORF73 among individuals with detectable KSHV in
PBMC39, consistent with our observations in this study. Contrary
to T cell responses to ORF73, T cell responses to K8.1 are higher
in those without KSHV DNA in PBMC, supporting the
hypothesis that the presence of KSHV-specific T cell responses
inhibits viral replication, hence reducing the risk of detecting the
virus in the blood. However, the frequency of this T cell response
in KSHV seropositive individuals without detectable viruses is
low, implying that there are other mechanisms through which
these individuals control the virus.
We also observe reactivity to SIV, a non-human primate virus.
This is very surprising because the SIV-CM9 peptide used in the
assay is restricted by a common class I allele (Mamu A*01) in
macaques. The equivalent epitope in HIV is also restricted by a
single HLA allele, yet all the study participants are HIV unin-
fected. Due to the limitations of sample availability, we could not
investigate this observation further, but this is most likely an
example of heterologous T cell reactivity.
The strength of this study is the large number of participants
compared to most past studies on KSHV T cell responses. In
addition, by focusing on HIV uninfected individuals from a
KSHV endemic area, as well as including a very wide age range of
individuals of both sexes, it allows us to provide a comprehensive
evaluation of the T-cell response across the age spectrum in
healthy individuals. An additional strength of this study is the use
of peptide pools that spanned the KSHV proteome.
In conclusion, IFN-γ T cell responses to KSHV are diverse and
when they do occur, they are not as intense as those against EBV,
CMV and influenza. However, the responses to particular anti-
gens (for example K8.1) may be more protective from viral
reactivation than others (for example ORF73/LANA). These
results provide insights into the potential success of immune
therapeutic vaccines in preventing or treating KS disease among
KSHV-infected individuals at high risk of developing KS.
Methods
Ethical approvals. This study is approved by the Uganda Virus Research Institute-
Research and Ethics Committee (reference number: GC/127/16/09/566), the
Uganda National Council for Science and Technology (reference number: HS2123)
and the London School of Hygiene and Tropical Medicine Ethics Committee
(reference number: 11881). Written informed consent was obtained from all adults
aged 18 years and above. Children below 18 years were consented to the study by
their parents or guardian; we also sought, in addition to parental consent, written
assent from children aged between 8 and 17 years. Transport refund is provided to
all invited study participants following Institution Review Board regulations and
approval.
KSHV ELISPOT assay. Overlapping 15mer peptides are synthesised to span nearly
the entire KSHV proteome, and peptides are divided into pools representing each
ORF20. Using these 83 peptide pools, working concentrations of 5 μg/ml/peptide
are prepared in 96-well culture plates using AIM-V media. The MABTECH
Human IFN-γ ELISpot kit (Code: 3420-2APT-10) is used for the assay, with a few
alterations to the manufacturer’s protocol. The ELISPOT plates with the capture
antibody from the kit are washed five times with 200 μl of 1× phosphate-buffered
saline (PBS) per well. Afterwards, thawed cells are added to the plates in a volume
of 100 μl containing 150,000 cells per well. The plates are covered with the lid and
wrapped in aluminium foil and transferred to a 5% CO2 37 °C incubator for a 24 h
resting period. To stimulate them, 100 μl per well of the peptide pools are added to
the cells. Anti-CD3, a pool of peptides from CMV EBV and Influenza (CEF) plus
EBV peptides alone are added as positive controls. Media and a non-human
antigen (SIV Gag CM9 peptide) are also added as negative controls. The plates are
then incubated at 37 °C for 46–48 h. Following stimulation, cells are washed five
Fig. 4 Proportion of individuals responding to atleast one KSHV ORF. .
Individuals categorized by age group (a) and sex (b).
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Fig. 5 Immune responses (IFN-y) and IgG antibody) to K8.1 and ORF73 as well as IFN-y responses to EBV and CMV+EBV+flu cocktail-CEF in
individuals with and without KSHV DNA in peripheral blood mononuclear cells (PBMC). a, g IFN-y responses to K8.1; b IgG antibody responses to K8.1;
c IgG antibody responses to ORF73; d, h IFN-y responses to ORF73; e IFN-y responses to EBV; f IFN-y responses to CEF.
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times with 200 μl of PBS per well and 100 μl of anti-human IFN-γ IgG conjugated
to alkaline phosphatase (Code: 7-B6-ALP) is added at a dilution of 1/200 in
PBS+ 0.5% FBS. The plates are incubated at room temperature (25 °C) for 2 h.
After the incubation, the plates are washed five times with 200 μl of 1× PBS per well
and 100 μl of filtered 5-bromo-4-chromo-3-indolyl-phosphate/nitroblue
tetrazolium-plus substrate (Code: 3650-10) are added per well. The plates are then
incubated at room temperature for 7 min and the reaction is stopped by washing
the plate with running tap water. The plates are dried in the dark overnight,
subsequently, the spots are counted using an ELISPOT reader (CTL ImmunoSpot
Analyzer (Cellular Technology Limited, Shaker Heights, USA)). This protocol has
been reported elsewhere20. K8.1 peptide pool and an EBV peptide pool were added
to the antigen panel at a later time during the ELISpot assay testing hence the first
40 samples missed being tested for these two antigens; 76 samples have a complete
panel of antigens including K8.1 and EBV. Peptide sequences for K8.1, EBV and
SIV are shown in Supplementary Table 1. Only plates with anti-CD3 responses are
included in the analysis. Anti-CD3, CEF and K8.1 SFC/million cells from the
76 samples with the complete antigen panel are shown in Supplementary Fig. 1.
K8.1 peptide deconvolution. The K8.1 peptide pool (of 44 peptides) is decon-
voluted in four study participants who responded to K8.1 peptide pool and had
enough PBMC for the assay. Using a grid-type method20, 14 smaller overlapping
peptide pools of six to seven peptides are generated. IFN-γ responses to the smaller
peptide pools are determined using the ELISPOT assay described above.
Responding individual peptides identified from the peptide matrix are confirmed
by stimulating with these individual responding peptides to run a third IFN-γ
ELISPOT assay. The sequences of the peptides identified in the four individuals are
10: VYQDWLGRMNCSYEN, 17: SEYPNVSVSVEDTSA, 22:
SGSGEEERPVTSHVT, 29: SGSYSSGEPSRTTRI, 30: SGEPSRTTRIRVSPV, 31:
RTTRIRVSPVAENGR, 34: NSGASNRVPFSATTT, 35: NRVPFSATTTTTRGR, 36:
SATTTTTRGRDAHYN, 37: TTRGRDAHYNAEIRT, 38: DAHYNAEIRTHLYIL,
41: WAVGLLLGLVLILYL, 43: LILYLCVPRCRRKKP, 44: YLCVPRCRRKKPYIV.
KSHV ELISA. Plasma samples from these individuals are tested for KSHV IgG
antibodies to K8.1 and ORF73 recombinant proteins to confirm seropositivity
following the procedure below. DynexImmulon 4 HBX 96-well plates (D17506,
Fisher catalogue number: NC9939836) are coated with 100 μl of K8.1 and ORF73
recombinant proteins at a dilution of 1:5000 for each protein. K8.1 protein is
diluted in 0.05 M carbonate/bicarbonate buffer, pH 10 and ORF73 in 1× PBS. The
plates are sealed using Nunc plate sealers and incubated in a fridge (4 °C) over-
night. After the overnight incubation, plates are washed three times with 350 μl of
wash solution (1× PBS, 0.05% Tween-20) per well, using an automated plate
washer (BioTek ELx405). They are then inverted and tapped dry on paper towels.
A volume of 270 μl assay buffer (2.5% bovine serum albumin-BSA (Sigma Che-
mical, catalogue number: A-7284) plus 2.5% normal donor goat serum (Equitech-
Bio catalogue number SG-0500) and 0.005% Tween-20 as well as 0.005% Triton
X-100 in 1× PBS) is added to each plate as a blocking agent, sealed with a plate
sealer, and incubated for 3 h at 37 °C and stored at −80 °C. To run the assay, plates
are thawed and washed three times with 350 μl of wash solution prior to adding
samples. Plasma samples and controls diluted 1:20 for K8.1 and 1:100 for ORF73 in
assay buffer are added to each plate in a volume of 100 μl. Plates are sealed and
incubated in a 37 °C incubator for 90 min. Each plate contains 88 samples, negative
and positive controls (each in triplicate) and a blank (assay buffer) in duplicate.
After the incubation, plates are washed five times with wash buffer, tapped dry on
paper towels, and 100 μl of goat anti-human IgG-Alkaline phosphatase labelled
conjugate (KPL catalogue number 4751-1002) at a dilution of 1:5000 in assay buffer
was added per well. Plates are then sealed and incubated at 37 °C for 30 min.
Following the 30 min incubation, plates are washed five times, tapped dry on a
paper towel, and 100 μl of 1-step p-nitrophenyl phosphate substrate solution is
added per well. They are then developed in the dark at room temperature for
30 min for ORF73 and 25 min for K8.1. Plates are then immediately read using a
microtiter plate reader (BioTek ELx808) at a wavelength of 405 nm. Optical den-
sities (ODs) are obtained. The ODs of the blank wells are used for background
subtraction for each sample and control. The positive and negative controls are
used for quality control, to determine if a plate had passed. The negative controls
are also used to calculate a cut-off value for each plate. The cut-off value for each
plate is the average background-subtracted OD of the three negative control tri-
plicates plus a constant value of 0.75 (for K8.1) or 0.35 (for ORF73).
KSHV PCR. KSHV viral load is quantified from PBMC KSHV seropositive study






























































Fig. 6 KSHV DNA levels in peripheral blood mononuclear cells (PBMC) by number of reactive peptide pools. (a) individuals grouped in 3 categories; (b)
individuals grouped in 5 categories.
Table 2 Identification of responding peptides within the K8.1 peptide pool (44 peptides).
Study participant
identification
Number of peptides (within K8.1 pool)
recognised per study participant
Peptides recognised (spot count per million PBMC)
GPC-313 7 10 (64), 17 (56), 30 (112), 34 (56), 35 (80), 36 (92), 41 (104)
GPC-69 10 22 (87), 29 (73), 31 (133), 34 (93), 36 (327), 37 (180), 38 (67),
41 (247), 43 (320), 44 (333)
GPC-339 1 44 (93)
GPC-371 2 43 (200), 44 (1627)
Ex vivo IFN-γ ELISpot assay was used to identify responding peptides within the K8.1 peptide pool using a grid-type method20. Sequences of responding peptides: 10: VYQDWLGRMNCSYEN, 17:
SEYPNVSVSVEDTSA, 22: SGSGEEERPVTSHVT, 29: SGSYSSGEPSRTTRI, 30: SGEPSRTTRIRVSPV, 31: RTTRIRVSPVAENGR, 34: NSGASNRVPFSATTT, 35: NRVPFSATTTTTRGR, 36:
SATTTTTRGRDAHYN, 37: TTRGRDAHYNAEIRT, 38: DAHYNAEIRTHLYIL, 41: WAVGLLLGLVLILYL, 43: LILYLCVPRCRRKKP, 44: YLCVPRCRRKKPYIV.
Source data are provided as a Source Data file.
PBMC peripheral blood mononuclear cell, GPC General Population Cohort.
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cells are removed, spun at 13,000 rcf for 10min to form cell pellets. The supernatants
are poured off and the cell pellets are stored at −80 °C. The PBMC pellets are retrieved
from the −80 °C freezer, thawed and genomic DNA extracted using a QIAamp blood
kit (Qiagen, Valencia, CA), following the manufacturer’s instructions. KSHV viral load
is quantified using real-time PCR. KSHV DNA is detected using primers (K6 forward
primer K6-10F 5′-CGCCTAATAGCTGCTGCTACGG-3′, K6 reverse primer K6-10R
5′-TGCATCAGCTGCCTAACCCAG-3′) and a probe (K6 probe p-K6-10 5′-R-
CACCCACCGCCCGTCCAAATTC-Q-3′) previously reported to be specific to the K6
gene region40. In addition, the number of cellular equivalents are determined using a
quantitative assay specific to human endogenous retrovirus 3 (ERV-3), which is present
in two copies per genomic cell, using these primers (ERV-3 Forward primer PHP10-F
5′-CATGGGAAGCAAGGGAACTAATG′ ERV-3 Reverse primer PHP10-R 5′-
CCCAGCGAGCAATACAGAATTT-3′) and a probe (ERV-3 Probe PHP-P505 5′-R-
TCTTCCCTCGAACCTGCACCATCAAGTCA-Q-3′). To quantify both ERV-3 and
KSHV DNA, seven two-fold serial dilutions of K6 and ERV-3 are made from clone
stocks (starting with 1 × 106 dilutions to 1 × 100) to form a standard curve on every
plate. ERV-3 was cloned into Bluescript II KS vector (Stratagene, La Jolla, CA, USA)
KSHV K6 cloned using PCR Topo II vector, Topo TA Cloning kit, Invitrogen, K 4600-
40. Primers (500 μl each), probes (500 μl), nuclease-free water (5.5ml) and universal
master mix (Applied Biosystems, Foster City CA) (12.5ml) are mixed together to form
the working solution master mix. Thereafter 10 μl of the standards, sample and controls
each, are added to a 96-well PCR plate (ThermoFisher catalogue number 7306737) per
well, in triplicate, and 40 μl of the working solution master mix added to each well. This
was followed by plate sealing and DNA amplification using an ABI ViiA7 machine. All
samples are tested in triplicate for both assays and the estimated copy number for each
individual reaction is averaged. The KSHV viral load is determined in PBMC DNA by
calculating the viral DNA copies per million cells. Any sample that is quantifiable by the
ERV-3 assay but not positive in all three reactions in the KSHV K6 assay is designated
as positive but not quantifiable. The lower limit of detection for the ERV-3 assay has
been previously determined as 10 copies per million cells while the KSHV K6 assay has
a lower limit of sensitivity of 1 copy per million cells. This procedure has been reported
elsewhere41–43. In order to prevent contamination, qPCR reagents, sample processing,
DNA extractions, and qPCR setup are conducted in dedicated laboratory areas. Internal
no template controls (NTC) were included on each plate, in triplicate, to assess cross-
contamination. Assay quality controls including NTC, assay controls and sample tri-
plicate % coefficient of variation are used to validate data. Importantly, the individual
dilution parameters of the assay standard curve are assessed after each run to ensure
performance within expected ranges. Any assay that has failures of assay controls or
standard curves is repeated.
Statistics and reproducibility
Study population and study design. The General Population Cohort (GPC) is a
community-based cohort of about 22,000 people living in 25 adjacent villages44,45, in
rural southwestern Uganda. Previously, we have documented a high seroprevalence
(>90%) of KSHV in the GPC46,47. For this study, we recruited individuals from the
GPC who were KSHV seropositive, but HIV seronegative in 2017, to investigate
determinants of KSHV viral detection. Only one individual was recruited per
household26. Blood samples were processed to isolate PBMC (stored in liquid
nitrogen for later immunological assays) and plasma (stored at −80 °C for later use).
Cell pellets containing two million PBMC were stored at −80 °C for later DNA
extraction. Details of the main study design have been reported previously26. KSHV-
specific T cell IFN-γ responses are determined in 116 participants aged 6–87 years.
No statistical method is used to predetermine sample size. Purposive sampling is used
to ensure that both male and female participants with and without detectable viral
DNA in PBMC from each age group are selected. Simple randomisation is used to
select individuals in each age group. Investigators are blinded to allocation during
experiments and recruitment. Details of the characteristics of the participants
(including the sex and age of participants) selected are shown in Table 1.
Graphical representation is done using GraphPad Prism 8.0.1 and STATA
version 13 (StataCorp, College Station, Texas USA). SFC per million PBMC are
calculated from the number of spots counted by the ELISpot reader and the
number of PBMC plated using Microsoft Office Excel (version 15.23). A cut-off of
40 SFC is applied. Therefore, individuals with SFC below 40 are considered non-
responders. χ2 test, Kruskal–Wallis test, Mann–Whitney (Wilcoxon rank-sum) test
are used for statistical analysis in STATA version 13 (StataCorp, College Station,
Texas USA). No data were excluded from the analysis.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data shown in all figures and tables generated in this study are provided in
the Supplementary information/Source Data file. Source Data are provided with
this paper.
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